The promise of antiretrovirals for HIV prevention

Current Infectious Disease Reports

Volumn 14, Issue 2, 2012, Pages 185-193

  Flash, Charlene ^a   Krakower, Douglas ^a   Mayer, Kenneth H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b FENWAY INSTITUTE   (United States)

Author keywords

Emtricitabine; HIV prevention; Microbicide; Pre exposure prophylaxis; Tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; DAPIVIRINE; EMTRICITABINE; MARAVIROC; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; PLACEBO; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; BONE DENSITY; CHEMOPROPHYLAXIS; CIRCUMCISION; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG UPTAKE; DRUG WITHDRAWAL; EARLY INTERVENTION; EXPERIMENTAL MODEL; FRACTURE; HARM REDUCTION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; KIDNEY INJURY; MACACA; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OCCUPATIONAL EXPOSURE; PATIENT ATTITUDE; PATIENT COMPLIANCE; POST EXPOSURE PROPHYLAXIS; PRE EXPOSURE PROPHYLAXIS; PREVENTIVE HEALTH SERVICE; PRIMATE DISEASE; PROPHYLAXIS; RETROVIRUS INFECTION; RISK REDUCTION; SIDE EFFECT; TREATMENT PLANNING; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; WEIGHT REDUCTION;

EID: 84862879462     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0242-z     Document Type: Article

References (92)

1. Centers for Disease Control and Prevention: High-Impact HIV Prevention. CDC's Approach to Reducing HIV Infections in the United States. Available at http://www.cdc.gov/hiv/strategy/dhap/pdf/nhas-booklet.pdf 2011. Accessed November 2011.
2. UNAIDS Report on the Global AIDS Epidemic http://www.unaids.org/ GlobalReport/default.htm] Accessed November 2011.
3. Granich R, Crowley S, Vitoria M, et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc. 2010;13:1.
4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365 (6):493-505. This reference reports the results of a multinational, randomized controlled trial, HPTN-052, in which immediate initiation of antiretroviral therapy by the HIV-infected member of HIV serodiscordant couples reduced the risk of HIV transmission to their HIV-uninfected partner by 96%, as compared to delaying antiretroviral therapy until a CD4 count of 250 cells/microliter or less was obtained.
5. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337(21):1485-90. (Pubitemid 27495773)
6. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr. 2008;47(4):494-9. (Pubitemid 351366963)
7. Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35(5):519-25. (Pubitemid 38420661)
8. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173-80. (Pubitemid 24331334)
9. Osmanov S, Pattou C, Walker N, et al. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr. 2002;29(2):184-90. (Pubitemid 34164892)
10. Boily MC, Baggaley RF,Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009;9(2):118-29.
11. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010;39 (4):1048-63.
12. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191(9):1403-9. (Pubitemid 40563350)
13. Vittinghoff E, Douglas J, Judson F, et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol. 1999;150(3):306-11. (Pubitemid 29344958)
14. Padian NS, Vittinghoff E, Shiboski S. Heterosexual transmission of HIV. N Engl J Med. 1994;331(25):1718. author reply 1718-1719.
15. Colfax GN, Buchbinder SP, Cornelisse PG, et al. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS. 2002;16(11):1529-35. (Pubitemid 34804218)
16. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2010. Cent Dis Contorl Prev Morb Mortal Wkly Rep. 2010;59:1-109.
17. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med. 1997;44(9):1303-12. (Pubitemid 27186886)
18. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002(1): CD003255.
19. Vanable PA, Carey MP, Brown JL, et al. What HIV-Positive MSM Want from sexual risk reduction interventions: findings from a qualitative study. AIDS Behav 2011.
20. Charnigo R, Crosby RA, Troutman A. Psychosocial constructs associated with condom use among high-risk African American men newly diagnosed with a sexually transmitted disease. Ann Behav Med. 2010;39(3):303-10.
21. Macaluso M, Demand MJ, Artz LM, Hook 3rd EW. Partner type and condom use. AIDS. 2000;14(5):537-46. (Pubitemid 30209696)
22. Ghimire L, Smith WC, van Teijlingen ER, et al. Reasons for nonuse of condoms and self-efficacy among female sex workers: a qualitative study in Nepal. BMC women's health. 2011;11(1):42.
23. Leval A, Sundstrom K, Ploner A, et al. Assessing perceived risk and STI prevention behavior: a national population-based study with special reference to HPV. PLoS One. 2011;6(6):e20624.
24. Kalichman SC, Williams EA, Cherry C, et al. Sexual coercion, domestic violence, and negotiating condom use among lowincome African American women. Journal of women's health/the official publication of the Society for the Advancement of Women's Health Research. 1998;7(3):371-8.
25. Wingood GM,DiClemente RJ. Partner influences and gender-related factors associated with noncondom use among young adult African American women. Am J Community Psychol. 1998;26(1):29-51. (Pubitemid 128689712)
26. Panchanadeswaran S, Frye V, Nandi V, et al. Intimate partner violence and consistent condom use among drug-using heterosexual women in New York City. Women Health. 2010;50(2):107-24.
27. Yesmont GA. The relationship of assertiveness to college students safer sex behaviors. Adolescence. 1992;27(106):253-72.
28. Mills E, Cooper C, Anema A, Guyatt G. Male circumcision for the prevention of heterosexually acquired HIV infection: a metaanalysis of randomized trials involving 11,050 men. HIV Med. 2008;9(6):332-5. (Pubitemid 352015640)
29. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control. 2006;55(RR-14):1-17.
30. Bendavid E, Brandeau ML, Wood R, Owens DK. Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med. 2010;170(15):1347-54.
31. Wodak A, Maher L. The effectiveness of harm reduction in preventing HIV among injecting drug users. N S W Public Health Bull. 2010;21(3-4):69-73.
32. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PloS one. 2010;5(6):e11068. This reference describes the relationship between community viral load, a novel measure of viral suppression on a community level, and HIV incidence.
33. Castel AD, Befus M, Willis S, et al. Use of the Community Viral Load as a Population-Based Biomarker of HIV Burden. Washington, DC: AIDS; 2011.
34. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921-9. (Pubitemid 30177052)
35. Hallett T, Baeten J, Heffron R, et al. ART or PrEP for HIV Prevention in HIV serodiscordant partnerships: a mathematical modeling comparison. In: 18th Conference on Retroviruses and Opportunistic Infections: 2011; Boston; 2011.
36. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med. 2011;364(20):1943-54.
37. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20(10):1447-50. (Pubitemid 43948252)
38. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission: Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. 2011: 1-207.
39. Centers for Disease C, Prevention: Achievements in public health. Reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR Morb Mortal Wkly Rep. 2006;55 (21):592-597.
40. Tissot F, Erard V, Dang T, Cavassini M. Nonoccupational HIV post-exposure prophylaxis: a 10-year retrospective analysis. HIV Med. 2010;11(9):584-92.
41. García-Lerma J, Otten R, Qari S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5(2):e28.
42. Garcia-Lerma JG, Cong Me, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):14ra14-4.
43. Parikh UM, Dobard C, Sharma S, et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol. 2009;83(20):10358-65.
44. Wilkinson D, Tholandi M, Ramjee G, Rutherford GW. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis. 2002;2(10):613-7.
45. Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25(7):957-66.
46. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977-87.
47. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallelgroup trial. Lancet. 2010;376(9749):1329- 37.
48. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5):463-72.
49. Pirrone V, Wigdahl B, Krebs FC. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res. 2011;90(3):168-82.
50. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-1174. This reference described the results of CAPRISA-004, a randomized controlled trial in which pericoital use of an intravaginal tenofovir gel by at-risk African women reduced the risk of HIV acquisition by 39%. This was the first demonstration of the efficacy of topical HIV pre-exposure prophylaxis.
51. Microbicide Trials Network Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women. Pittsburgh: Microbicide Trials Network, 2011.
52. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20 (4):543-51. (Pubitemid 43731598)
53. Nuttall J, Kashuba A, Wang R, et al. The pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob Agents Chemother. 2011, epublished ahead of print.
54. Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIVnegative women. J Acquir Immune Defic Syndr. 2009;51 (5):546-53.
55. Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009;51 (4):416-23.
56. Singer R, Derby N, Rodriguez A, et al. The Nonnucleoside Reverse Transcriptase InhibitorMIV-150 in Carrageenan Gel Prevents Rectal Transmission of Simian/Human Immunodeficiency Virus Infection in Macaques. J Virol. 2011;85(11):5504-12.
57. McElrath MJ, Ballweber L, Terker A, et al. Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrob Agents Chemother. 2010;54(2):763-72.
58. Malcolm RK, Edwards KL, Kiser P, et al. Advances in microbicide vaginal rings. Antiviral Res. 2010;88:S30-9.
59. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-9.
60. Beyrer C, Baral SD, Walker D, et al. The expanding epidemics of HIV type 1 among men who have sex with men in low-and middle-income countries: diversity and consistency. Epidemiol Rev. 2010;32(1):137-51.
61. Anton P, Cranston R, Carballo-Dieguez, A et al. RMP-02/MTN-006: a Phase 1 Placebo-controlled Trial of Rectally Applied 1% Vaginal TFV Gel with Comparison to Oral TDF. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston; 2011.
62. Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20 (5):731-9. (Pubitemid 43884301)
63. Anton PA, Saunders T, Elliott J, et al. First Phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 Gel with a novel index of ex vivo efficacy. PLoS One. 2011;6(9):15.
64. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363(27):2587- 2599. This reference describes the results of a multinational, randomized controlled trial, the iPrEx study. This study demonstrated that adminstration of oral preexposure prophylaxis with a once-daily fixed-dose combination tablet containing emtricitabine and tenofovir decreased the risk of HIV acquisition among at-risk men who have sex with men by 44% as compared to placebo.
65. Early end for FEM-PrEP HIV prevention trial. AIDS Patient Care STDS. 2011;25(6):383.
66. Thigpen MC KP, Smith DK, Segolodi TM, et al for the TDF2 Study Group: Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study.[ Abstract WELBC01] Presented at International AIDS Society: 2011; Rome, Italy; July 17-20, 2011.
67. Baeten J, Celum C: Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention among Heterosexual African Men and Women: The Partners PrEP Study. [Abstract MOAX0106]. Presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Rome, Italy; July 17-20, 2011.
68. Schwartz JL, Rountree W, Kashuba AD, et al. A multicompartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One. 2011;6(10):e25974.
69. Microbicides Trial Network: Fact Sheet for The VOICE Study: Vaginal and Oral Interventions to Control the Epidemic. Available at http://www.mtnstopshiv. org/node/2003. Accessed November 2011.
70. Mutua GSE, Kamali A, Kibengo F, et al. Safety and adherence to intermittent emtricitabine/tenofovir for HIV pre-exposure prophylaxis (PrEP) in Kenya and Uganda. In: International AIDS Society. Vienna; 2010.
71. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis. 2008;46(5):719-25. (Pubitemid 351321556)
72. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. In.: Department of Health and Human Services; Available at http://aidsinfo.nih. gov/contentfiles/AdultandAdolescentGL.pdf Accessed November 2011; 1-167.
73. Hurt CB, Eron Jr JJ. Cohen MS: pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis. 2011;53(12):1265-70.
74. Abbas U, Glaubius R, Mubayi A, et al. Predicting the Impact of ART and PrEP with Overlapping Regimens on HIV Transmission and Drug Resistance in South Africa. In: 18th Conference on Retroviruses and Opportunistic Infections: 2011; Boston, Massachusetts; 2011.
75. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS One. 2011;6(4):e18165.
76. Cooper Ryan D, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.
77. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, doubleblind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2(5):e27.
78. Grohskopf LGR, Pathak S, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM). In: XVIII International AIDS Conference. Vienna, Austria; 2010.
79. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49 (3):298-308.
80. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6(8):e23688.
81. Mulligan K, Glidden DV, Gonzales P, et al. Effects of FTC/TDF on Bone Mineral Density in Seronegative Men from 4 Continents: DEXA Results of the Global iPrEx Study. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston; 2011.
82. Hendrix C, Minnis A, Guddera V, et al. MTN-001: a Phase 2 Crossover Study of Daily Oral and Vaginal TFVin Healthy, Sexually Active Women Results in Significantly Different Product Acceptability and Vaginal Tissue Drug Concentrations. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston; 2011.
83. Galea JT, Kinsler JJ, Salazar X, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256-62.
84. Mimiaga MJ, Case P, Johnson CV, et al. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77-83.
85. Martin S, Blanchard K, Manopaiboon C, et al. Carraguard acceptability among men and women in a couples study in Thailand. J Womens Health (Larchmt). 2010;19(8):1561-7.
86. Interim Guidance. Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men. MMWR Morb Mortal Wkly Rep 2011;60(3):65-68. This reference describes interim guidance from the US Centers for Disease Control and Prevention for healthcare providers regarding implementation of pre-exposure prophylaxis among at-risk men who have sex with men.
87. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48 (6):806-15.
88. Hallett TB, Baeten J, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8(11).
89. Trends in HIV prevalence and sexual behaviour among young people aged 15-24 years in countries most affected by HIV. Sex Transm Infect. 2010;86 Suppl 2:ii72-ii83.
90. Prejean J, Song R, Hernandez A, et al. Estimated HIV Incidence in the United States, 2006-2009. PLoS One. 2011;6(8):e17502.
91. AIDS Vaccine Advocacy Coalition. Ongoing Clinical Trials of Topical Microbicide Candidates. Last updated August 2011. Available at http://www.ava4c.org/ht/a/GetDocumentAction/i/3109. Accessed November 2011.
92. International Partnership for Microbicides: Clinical Trials Table. Last updated October 2011 Available at http://www.ipmglobal.org/ our-work/research/ clinical-trial. Accessed November 2011.